Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Prescient Therapeutics Limited ( (AU:PTX) ) is now available.
Prescient Therapeutics Limited has announced a proposed issue of 175,000,000 ordinary fully paid securities under a securities purchase plan. This move is aimed at raising capital, which could potentially enhance the company’s financial position and support its ongoing research and development efforts in cancer therapies.
More about Prescient Therapeutics Limited
Prescient Therapeutics Limited operates in the biotechnology industry, focusing on the development of innovative cancer therapies. The company is dedicated to advancing its pipeline of targeted and personalized medicine solutions to improve cancer treatment outcomes.
Average Trading Volume: 859,643
Technical Sentiment Signal: Sell
Current Market Cap: A$37.04M
Find detailed analytics on PTX stock on TipRanks’ Stock Analysis page.